Ingersoll Rand Acquires Scinomix, Strengthens Life Sciences Portfolio

Ingersoll Rand Inc. IR recently completed the acquisition of a leading automation workflow technology provider — Scinomix, Inc. The financial terms of the transaction were kept under wraps.Ingersoll Rand’s shares were up 3.1% yesterday to eventually close the trading session at $82.21.Headquartered in Earth City, MO, Scinomix specializes in manufacturing advanced technologies that facilitate streamlining automation workflows across several industries. The company’s products are used for labeling, barcode scanning, and capping lab equipment like vials, tubes and microplates.Acquisition RationaleThe latest buyout is in sync with Ingersoll Rand’s policy of acquiring businesses to expand its market share and customer base. The inclusion of Scinomix’s expertise in automation technologies, coupled with its strong innovation capabilities, will enable Ingersoll Rand to boost its life sciences products portfolio. It will also help IR expand its presence in lucrative end markets like pharmaceutical, clinical, biotechnology, genetic testing laboratories and agricultural.Scinomix will be incorporated into Ingersoll Rand’s Life Sciences platform under the Precision and Science Technologies segment. The segment is engaged in manufacturing products, including fluid management equipment, powder containment and aftermarket parts for medical, laboratory, pharmaceutical and biopharmaceutical production.Zacks Rank, Price Performance and Estimate RevisionsIngersoll Rand, with approximately $32.7 billion market capitalization, currently carries a Zacks Rank #4 (Sell). The company’s growth-based investments are pushing up costs with a corresponding negative effect on the bottom line. Also, a high debt level may increase its financial obligations in the quarters ahead. However, it is set to gain from a healthy demand environment and innovation capabilities.Image Source: Zacks Investment ResearchIn the past year, the company’s shares have lost 7.8% against the industry’s growth of 9.6%.The Zacks Consensus Estimate for its earnings is pegged at $3.29 for 2025, suggesting a decrease of 0.6% from the 60-day-ago figure.Key PicksSome better-ranked stocks from the same space are presented below.DXP Enterprises DXPE carries a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.In the past 60 days, the Zacks Consensus Estimate for DXP Enterprises’ 2025 earnings has increased 5.9%.Nordson Corporation NDSN presently has a Zacks Rank of 2. Nordson delivered a trailing four-quarter average earnings surprise of 2.2%. In the past 60 days, the Zacks Consensus Estimate for Nordson’s fiscal 2026 (ending October 2026) earnings has increased 2.3%.Trimble Inc. TRMB currently carries a Zacks Rank of 2. TRMB delivered a trailing four-quarter average earnings surprise of 7.4%. In the past 60 days, the Zacks Consensus Estimate for Trimble’s 2025 earnings has increased 3.3%.Just Released: Zacks Top 10 Stocks for 2026Hurry – you can still get in early on our 10 top tickers for 2026. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful.From inception in 2012 through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2026. You can still be among the first to see these just-released stocks with enormous potential.See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Trimble Inc. (TRMB): Free Stock Analysis Report Ingersoll Rand Inc. (IR): Free Stock Analysis Report Nordson Corporation (NDSN): Free Stock Analysis Report DXP Enterprises, Inc. (DXPE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks